

PID Q4 2019-20

Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
235876	BREEZE-AD4: Baricitinib in moderate to severe atopic dermatitis	Number Agreed	4	4	Date Agreed	28/02/2019	1	24/05/2019	1	Recruitment Finished	Difficult to recruit to
231258	JBT101-SSc-002 Efficacy & Safety Study of Lenabasum in SSc	Number Agreed	2	2	Date Agreed	29/03/2019	4	30/04/2019	4	Recruitment Finished	difficult to recruit to
215706	CARD 4983 GALACTIC-HF	Number Agreed	15	15	Date Agreed	31/05/2019	17	09/07/2019	17	Recruitment Finished	
250624	A Phase 3 study of BMS-986165 in participants with plaque psoriasis	Number Agreed	2	2	Date Agreed	15/07/2019	1	14/10/2019	1	Recruitment Finished	Competative recruitment
253279	Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA	Number Agreed	3	3	Date Agreed	19/12/2019	0	19/03/2020	0	Withdrawn By Sponsor	withdrawn early due to COVID 19pandemic
251974	Tralokinumab in moderate-severe AD	Number Agreed	9	9	Date Agreed	28/11/2018	9	01/02/2020	9	Recruitment Finished	new measures for dispensing IMP had to be put in place

	extension trial 1337											due to COVID 19 pandemic.
--	-------------------------	--	--	--	--	--	--	--	--	--	--	------------------------------